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Why study hereditary periodic-fever syndromes, 
which affect fewer than 500 patients worldwide? 
The discovery of cryopyrin provides an answer. 
The story begins in 2001, when investigators 
showed that mutations in the cold-induced auto-
inflammatory syndrome 1 (CIAS1) gene, which 
encodes cryopyrin, causes two hereditary periodic-
fever disorders: the Muckle–Wells syndrome and 
the familial cold autoinflammatory syndrome.1 
The following year, a third periodic-fever syn-
drome (also referred to as neonatal-onset multi-
system inflammatory disease or the chronic in-
fantile neurologic, cutaneous, articular syndrome) 
was found to be caused by mutant cryopyrin.2,3 
Three articles recently published in Nature 4-6 now 
suggest that by discovering cryopyrin, the re-
searchers stumbled on the Rosetta stone of in-
nate immunity: a highly conserved and specific 
response system that detects the presence of mi-
croorganisms.
Macrophages and neutrophils contain the in-
flammasome, a complex of proteins that have 
distinct roles in the innate defense system. Mem-
bers of the “NALP” family of proteins (which in-
cludes cryopyrin) are the main building blocks 
of the inflammasome. Two types of inflamma-
some have now been described in detail — the 
NALP1 inflammasome and the NALP3, or cryo-
pyrin, inflammasome — but there are probably 
many more variants. The stimulation of cryo-
pyrin within the cryopyrin inflammasome trig-
gers a series of internal reactions that ultimately 
result in the activation of the proinflammatory 
cytokine interleukin-1β. This interleukin is, in 
turn, secreted by the macrophage and triggers 
another cascade of molecular events that result in 
inflammation. The inflammasome was hypoth-
esized to act as an early sensor to detect danger 
signals threatening the cell and to set the wheels 
of host defense in motion. Although this hypoth-
esis was attractive, the events critical to the as-
sembly, and hence the activation, of the inflam-
masome were unknown.
The three recently reported studies by Kanne-
ganti et al.,4 Martinon et al.,5 and Mariathasan 
et al.6 had similar designs: each group engi-
neered mice in which cryopyrin in the macro-
phages was knocked out and studied the response 
of these macrophages to various danger signals. 
They found that the ability of cryopyrin-deficient 
macrophages to secrete activated interleukin-1β 
was significantly reduced under specific circum-
stances.
Kanneganti et al.4 and Mariathasan et al.6 
focused on the role of the cryopyrin inflamma-
some in the detection of infectious agents. Kanne-
ganti et al. showed that macrophages that lack 
cryopyrin neither produce active interleukin-1β 
in response to bacterial RNA nor respond to ei-
ther of two vaccine adjuvants. Mariathasan et al.
showed that cryopyrin-deficient macrophages do 
not respond efficiently to challenges with Staphy-
lococcus aureus or Listeria monocytogenes. Both groups 
demonstrated the specificity of the cryopyrin in-
flammasome. For example, Mariathasan et al. 
showed that the recognition of the gram-nega-
tive bacteria Salmonella typhimurium and Francisella 
tularensis by the macrophage is not dependent on 
the presence of cryopyrin but requires other com-
mon inflammasome components.
Martinon et al.5 studied the role of cryopyrin 
in the detection of urate crystals. It has been 
known for more than 200 years that the deposi-
tion of such crystals causes joint inflammation 
in patients with gout, but how it does so was un-
clear. These researchers showed that both mono-
sodium urate (the crystal in gout) and calcium 
pyrophosphate dehydrate (the crystal in pseudo-
gout) are detected by the cryopyrin inflamma-
some, which then initiates the inflammatory 
cascade by activating interleukin-1β. The inflam-
masome appears to be key in the initiation: peri-
toneal macrophages from mice deficient in other 
components of the cryopyrin inflammasome, 
such as procaspase-1 (Fig. 1), did not produce 
interleukin-1β in response to the injection of 
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Figure 1. The Cryopyrin Inflammasome.
Cryopyrin, or NALP3, is the central component of the cryopyrin inflammasome. Cryopyrin contains three domains: 
a pyrin domain (PYD), a nucleoside oligomerization domain (NOD), and a domain of leucine-rich repeats (LRR). 
The other components of the cryopyrin inflammasome ASC — apoptosis-associated speck-like protein containing 
a caspase recruitment domain (CARD), cardinal, and procaspase-1 (Panel A) — consist of domains that can be assem-
bled only after cryopyrin is activated through the interaction of its LRR domain with either a crystal (urate or calcium 
pyrophosphate dehydrate) or certain microbial species (Panel B). The assembly of the domains ultimately leads to 
the release of active caspase-1, which in turn activates interleukin-1β through the cleavage of pro–interleukin-1β. 
On its secretion into the extracellular milieu, interleukin-1β sets off a series of events that result in inflammation. 
FIIND denotes the domain with function to find.
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urate crystals. The study5 also indicates that cryo-
pyrin is rather choosy: harmless particles such as 
diamond crystals or aluminum powder do not 
act as a trigger.
Although the three studies have minor discrep-
ancies that need to be resolved, they catapult 
cryopyrin from involvement in a rather obscure 
group of disorders into the realm of common 
bacterial infections and of gout, which alone af-
fects at least 1 in every 400 persons in the United 
States.
The cryopyrin inflammasome would seem to 
be a versatile sentry of the innate immune sys-
tem, and it is easy to speculate on the possible 
future therapeutic implications of these findings. 
In fact, clinical treatment based on the mecha-
nism of disease has already been realized for the 
three rare diseases that led to the discovery of 
cryopyrin. Most of the mutations that cause the 
hereditary periodic-fever syndromes result in a 
hyperactive cryopyrin, thus leading to the in-
creased secretion of interleukin-1β. Clinical trials 
have shown that the interleukin-1 receptor antag-
onist anakinra effectively ameliorates clinical 
symptoms in all three syndromes. By modifying 
the cryopyrin inflammasome, we might protect 
against diverse microorganisms, increase the ef-
ficacy of vaccines, and ease the inflammatory 
arthritis characteristic of gout and pseudogout.
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